Xtacy Therapeutics Corp.
Pegasus Mercantile Inc. is an incubator, venture capital firm specializing in incubation, startup and early stage. The firm seeks to invest in the public and private sectors that focus on preventative health, wellness issues, related consumer products, biotechnology, specific areas of pain, Psychedelic, depression, mental illness health and medicine sectors. By investing in pioneering techniques … Read more
Market Cap & Net Worth: Xtacy Therapeutics Corp. (XTCYF)
Xtacy Therapeutics Corp. (PINK:XTCYF) has a market capitalization of $292.79K ($292.79K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #38747 globally and #12579 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xtacy Therapeutics Corp.'s stock price $0.02 by its total outstanding shares 13369567 (13.37 Million).
Xtacy Therapeutics Corp. Market Cap History: 2018 to 2025
Xtacy Therapeutics Corp.'s market capitalization history from 2018 to 2025. Data shows change from $14.92 Million to $292.79K (-43.89% CAGR).
Xtacy Therapeutics Corp. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xtacy Therapeutics Corp.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.74x
Xtacy Therapeutics Corp.'s market cap is 4.74 times its annual revenue
1.83x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.70 Million | $101.87K | -$1.37 Million | 26.51x | N/A |
| 2023 | $1.06 Million | $25.65K | -$455.91K | 41.33x | N/A |
| 2024 | $278.09K | $58.72K | -$546.01K | 4.74x | N/A |
Competitor Companies of XTCYF by Market Capitalization
Companies near Xtacy Therapeutics Corp. in the global market cap rankings as of March 18, 2026.
Key companies related to Xtacy Therapeutics Corp. by market ranking:
- Visa Inc. Class A (NYSE:V): Ranked #20 globally with a market cap of $536.66 Billion USD.
- Mastercard Inc (NYSE:MA): Ranked #24 globally with a market cap of $450.90 Billion USD.
- American Express Company (NYSE:AXP): Ranked #102 globally with a market cap of $160.20 Billion USD.
- Capital One Financial Corporation (NYSE:COF): Ranked #173 globally with a market cap of $111.74 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #20 | Visa Inc. Class A | NYSE:V | $536.66 Billion | $308.46 |
| #24 | Mastercard Inc | NYSE:MA | $450.90 Billion | $506.58 |
| #102 | American Express Company | NYSE:AXP | $160.20 Billion | $300.27 |
| #173 | Capital One Financial Corporation | NYSE:COF | $111.74 Billion | $183.42 |
Xtacy Therapeutics Corp. Historical Marketcap From 2018 to 2025
Between 2018 and today, Xtacy Therapeutics Corp.'s market cap moved from $14.92 Million to $ 292.79K, with a yearly change of -43.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $292.79K | +5.29% |
| 2024 | $278.09K | -73.77% |
| 2023 | $1.06 Million | -29.51% |
| 2022 | $1.50 Million | -30.08% |
| 2021 | $2.15 Million | -20.35% |
| 2020 | $2.70 Million | +1.00% |
| 2019 | $2.67 Million | -82.08% |
| 2018 | $14.92 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Xtacy Therapeutics Corp. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $292.79K USD |
| MoneyControl | $292.79K USD |
| MarketWatch | $292.79K USD |
| marketcap.company | $292.79K USD |
| Reuters | $292.79K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.